Literature DB >> 20097732

In vivo analysis of p53 tumor suppressor function using genetically engineered mouse models.

Daniela Kenzelmann Broz1, Laura D Attardi.   

Abstract

p53 is a crucial tumor suppressor, as evidenced by the high propensity for p53 mutation during human cancer development. Already more than a decade ago, p53 knockout mice confirmed that p53 is critical for preventing tumorigenesis. More recently, a host of p53 knock-in mouse strains has been generated, with the aim of either more precisely modeling p53 mutations in human cancer or better understanding p53's regulation and downstream activities. In the first category, several mouse strains expressing mutant p53 proteins corresponding to human-tumor-derived mutants have demonstrated that mutant p53 is not equivalent to loss of p53 but additionally exhibits gain-of-function properties, promoting invasive and metastatic phenotypes. The second class of p53 knock-in mouse models expressing engineered p53 mutants has also provided new insight into p53 function. For example, mice expressing p53 mutants lacking specific posttranslational modification sites have revealed that these modifications serve to modulate p53 responses in vivo in a cell-type- and stress-specific manner rather than being absolutely required for p53 stabilization and activation as suggested by in vitro experiments. Additionally, studies of p53 mouse models have established that both p53-driven cell-cycle arrest and apoptosis responses contribute to tumor suppression and that activation of p53 by oncogenic stress imposes an important barrier to tumorigenesis. Finally, the use of mouse strains expressing temporally regulatable p53 has demonstrated that p53 loss is not only required for tumor development but also required for tumor maintenance, suggesting that p53 restoration in human cancer patients may be a promising therapeutic strategy. These sophisticated p53 mouse models have taught us important lessons, and new mouse models will certainly continue to reveal interesting and perhaps surprising aspects of p53's complex biology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20097732      PMCID: PMC2915627          DOI: 10.1093/carcin/bgp331

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  64 in total

Review 1.  Live or let die: the cell's response to p53.

Authors:  Karen H Vousden; Xin Lu
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

2.  Modulation of mammalian life span by the short isoform of p53.

Authors:  Bernhard Maier; Wendy Gluba; Brian Bernier; Terry Turner; Khalid Mohammad; Theresa Guise; Ann Sutherland; Michael Thorner; Heidi Scrable
Journal:  Genes Dev       Date:  2004-02-01       Impact factor: 11.361

Review 3.  Transcriptional control of human p53-regulated genes.

Authors:  Todd Riley; Eduardo Sontag; Patricia Chen; Arnold Levine
Journal:  Nat Rev Mol Cell Biol       Date:  2008-05       Impact factor: 94.444

4.  p53 mutant mice that display early ageing-associated phenotypes.

Authors:  Stuart D Tyner; Sundaresan Venkatachalam; Jene Choi; Stephen Jones; Nader Ghebranious; Herbert Igelmann; Xiongbin Lu; Gabrielle Soron; Benjamin Cooper; Cory Brayton; Sang Hee Park; Timothy Thompson; Gerard Karsenty; Allan Bradley; Lawrence A Donehower
Journal:  Nature       Date:  2002-01-03       Impact factor: 49.962

Review 5.  Germline TP53 mutations and Li-Fraumeni syndrome.

Authors:  J M Varley
Journal:  Hum Mutat       Date:  2003-03       Impact factor: 4.878

6.  Phosphorylation of serine 18 regulates distinct p53 functions in mice.

Authors:  Hayla K Sluss; Heather Armata; Judy Gallant; Stephen N Jones
Journal:  Mol Cell Biol       Date:  2004-02       Impact factor: 4.272

7.  Increased sensitivity to UV radiation in mice with a p53 point mutation at Ser389.

Authors:  Wendy Bruins; Edwin Zwart; Laura D Attardi; Tomoo Iwakuma; Esther M Hoogervorst; Rudolf B Beems; Barbara Miranda; Conny T M van Oostrom; Jolanda van den Berg; Gerard J van den Aardweg; Guillermina Lozano; Harry van Steeg; Tyler Jacks; Annemieke de Vries
Journal:  Mol Cell Biol       Date:  2004-10       Impact factor: 4.272

8.  Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23.

Authors:  David MacPherson; Jungho Kim; Teresa Kim; Byung Kirl Rhee; Conny Th M Van Oostrom; Richard A DiTullio; Monica Venere; Thanos D Halazonetis; Roderick Bronson; Annemieke De Vries; Mark Fleming; Tyler Jacks
Journal:  EMBO J       Date:  2004-09-02       Impact factor: 11.598

9.  Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice.

Authors:  Geng Liu; John M Parant; Gene Lang; Patty Chau; Arturo Chavez-Reyes; Adel K El-Naggar; Asha Multani; Sandy Chang; Guillermina Lozano
Journal:  Nat Genet       Date:  2003-12-21       Impact factor: 38.330

10.  Cell type- and promoter-specific roles of Ser18 phosphorylation in regulating p53 responses.

Authors:  Connie Chao; Manfred Hergenhahn; Matthias D Kaeser; Zhiqun Wu; Shin'ichi Saito; Richard Iggo; Monica Hollstein; Ettore Appella; Yang Xu
Journal:  J Biol Chem       Date:  2003-08-08       Impact factor: 5.157

View more
  38 in total

1.  Using targeted transgenic reporter mice to study promoter-specific p53 transcriptional activity.

Authors:  Amanda M Goh; Chin Yan Lim; Poh Cheang Chiam; Ling Li; Michael B Mann; Karen M Mann; Sergio Menendez; David P Lane
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

Review 2.  p53 at a glance.

Authors:  Colleen A Brady; Laura D Attardi
Journal:  J Cell Sci       Date:  2010-08-01       Impact factor: 5.285

3.  Global genomic profiling reveals an extensive p53-regulated autophagy program contributing to key p53 responses.

Authors:  Daniela Kenzelmann Broz; Stephano Spano Mello; Kathryn T Bieging; Dadi Jiang; Rachel L Dusek; Colleen A Brady; Arend Sidow; Laura D Attardi
Journal:  Genes Dev       Date:  2013-05-01       Impact factor: 11.361

4.  Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression.

Authors:  Colleen A Brady; Dadi Jiang; Stephano S Mello; Thomas M Johnson; Lesley A Jarvis; Margaret M Kozak; Daniela Kenzelmann Broz; Shashwati Basak; Eunice J Park; Margaret E McLaughlin; Anthony N Karnezis; Laura D Attardi
Journal:  Cell       Date:  2011-05-13       Impact factor: 41.582

5.  Interaction of the oncogenic miR-21 microRNA and the p53 tumor suppressor pathway.

Authors:  Xiaodong Ma; Saibyasachi N Choudhury; Xiang Hua; Zhongping Dai; Yong Li
Journal:  Carcinogenesis       Date:  2013-02-05       Impact factor: 4.944

Review 6.  Mouse models for liver cancer.

Authors:  Latifa Bakiri; Erwin F Wagner
Journal:  Mol Oncol       Date:  2013-02-05       Impact factor: 6.603

7.  Amino-terminal p53 mutations lead to expression of apoptosis proficient p47 and prognosticate better survival, but predispose to tumorigenesis.

Authors:  Beng Hooi Phang; Rashidah Othman; Gaelle Bougeard; Ren Hui Chia; Thierry Frebourg; Choong Leong Tang; Peh Yean Cheah; Kanaga Sabapathy
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-02       Impact factor: 11.205

8.  An extra copy of p53 suppresses development of spontaneous Kras-driven but not radiation-induced cancer.

Authors:  Everett J Moding; Hooney D Min; Katherine D Castle; Moiez Ali; Loretta Woodlief; Nerissa Williams; Yan Ma; Yongbaek Kim; Chang-Lung Lee; David G Kirsch
Journal:  JCI Insight       Date:  2016-07-07

Review 9.  Oxidative stress and pulmonary fibrosis.

Authors:  Paul Cheresh; Seok-Jo Kim; Sandhya Tulasiram; David W Kamp
Journal:  Biochim Biophys Acta       Date:  2012-12-05

Review 10.  Molecular basis of asbestos-induced lung disease.

Authors:  Gang Liu; Paul Cheresh; David W Kamp
Journal:  Annu Rev Pathol       Date:  2013-01-24       Impact factor: 23.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.